The Two-Marker CAR-T Test: LNK001's First Patients and the Safety Hypothesis
Dr. Dereck Mush, MD, MBABiotech
The science companies behind the medicines: pipelines, platforms, trials and the moment a lab result becomes a therapy.
Dr. Dereck Mush, MD, MBA
Beyond the Genetic Ceiling: How Scholar Rock's FDA Approval for Isembyld Unlocks the Muscle-Directed Neuromuscular Economy
Dr. Dereck Mush, MD, MBA
An oral GLP-1 pill enters Phase 3, and the obesity race gets a new lane
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
